September 23, 2026

Uncategorized

Ittihad announces Half Year 2024 Financial Results

Steady Growth and Resilience ABU DHABI, United Arab Emirates, Sept. 04, 2024 (GLOBE NEWSWIRE) — Ittihad International Investment LLC (“Ittihad”; the “Company”), the leading industrial conglomerate in the UAE, today announces its Half Year 2024 Financial Results. Financial Highlights – H1 2024 vs H1 2023 Group Revenue of $1.6 billion (AED6.0 billion) vs $1.5 billion […]

Read More

Grath Expands Operations to The Middle East

LONDON, Sept. 04, 2024 (GLOBE NEWSWIRE) — Grath, a leading global platform for financial services and regulatory compliance technology, is excited to announce its strategic expansion into the Middle East with the opening of a new office in the prestigious Dubai International Finance Centre (DIFC). This expansion marks a significant milestone in Grath’s mission to provide world-class financial services, […]

Read More

Grath Expands Operations to The Middle East

LONDON, Sept. 04, 2024 (GLOBE NEWSWIRE) — Grath, a leading global platform for financial services and regulatory compliance technology, is excited to announce its strategic expansion into the Middle East with the opening of a new office in the prestigious Dubai International Finance Centre (DIFC). This expansion marks a significant milestone in Grath’s mission to provide world-class financial services, […]

Read More

Abu Dhabi set to host AIM Congress 2025 in April

ABU DHABI: The Organising Committee of AIM Congress has announced that the 14th edition of AIM Congress will take place from 7th to 9th April 2025, under the theme “Mapping the Future of Global Investment: The New Wave of a Globalised Investment Lands…

Read More

Recursion Announces Phase 2 Data of REC-994, a First-in-Disease Investigational Treatment for Symptomatic Cerebral Cavernous Malformation (CCM), has Met its Primary Endpoint of Safety and Tolerability

REC-994 also demonstrates encouraging trends in objective MRI-based exploratory efficacy measures at the highest dose and the company plans to advance development of REC-994 for the potential treatment of symptomatic CCM in subsequent studies. SALT LAKE CITY, Sept. 03, 2024 (GLOBE NEWSWIRE) — Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to […]

Read More

Recursion Announces Phase 2 Data of REC-994, a First-in-Disease Investigational Treatment for Symptomatic Cerebral Cavernous Malformation (CCM), has Met its Primary Endpoint of Safety and Tolerability

REC-994 also demonstrates encouraging trends in objective MRI-based exploratory efficacy measures at the highest dose and the company plans to advance development of REC-994 for the potential treatment of symptomatic CCM in subsequent studies. SALT LAKE CITY, Sept. 03, 2024 (GLOBE NEWSWIRE) — Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to […]

Read More